E. Nizankowska (Krakow, Poland), J. C. Virchow (Rostock, Germany)
Long-term asthma control with omalizumab, an anti-IgE monoclonal antibody, in patients with severe allergic asthma
K. Chung, J. Ankerst, M. Rolli, J. Gao, C. Reisner (London, United Kingdom; Lund, Sweden; East Hanover, United States Of America)
|  |
Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age
R. Buhl, H. Fox, M. Blogg, C. Reisner (Mainz, Germany; Horsham, United Kingdom; East Hanover, United States Of America)
| |
Omalizumab significantly improves FEV1 in patients with severe persistent allergic asthma: a pooled analysis
S. Holgate, H. Fox, S. Hedgecock, P. Freeman, C. Reisner (Southampton, Horsham, United Kingdom; East Hanover, United States Of America)
| |
Improved disease control in asthmatics treated with daclizumab is not associated with changes in allergen-specific or total IgE
W. W. Busse, E. Israel, H. E. Nelson, V. Vexler, M. H. Wang, R. S. Shames (Madison, Boston, Denver, Fremont, United States Of America)
| |
Long-term safety and tolerability of omalizumab, an anti-IgE monoclonal antibody, in patients with severe allergic asthma
A. Chuchalin, J. Herbert, M. Rolli, J. Gao, C. Reisner (Moscow, Russian Federation; , ; East Hanover, United States Of America)
| |
Evaluating response to omalizumab (anti-IgE) in clinical practice
G. Ayre, H. Fox, H. Chen, S. Hedgecock, C. Reisner (Horsham, United Kingdom; East Hanover, United States Of America)
| |
Physicians judge add-on omalizumab therapy as an effective treatment for patients with severe persistent allergic asthma: a pooled analysis
M. Humbert, H. Fox, S. Hedgecock, G. Ayre, P. Freeman, C. Reisner (Clamart, France; Horsham, United Kingdom; East Hanover, United States Of America)
| |
Omalizumab significantly improves quality of life in patients with severe persistent allergic asthma: a pooled analysis
K. M. Beeh, H. Fox, P. Freeman, S. Hedgecock, C. Reisner (Wiesbaden, Germany; Horsham, United Kingdom; East Hanover, United States Of America)
| |
Effect of lidocaine delivered by a hand-held metered-dose inhaler on steroid-resistant asthma
K. Yin, X. Zhang (Nanjing, China)
| |
Effect of tiotropium bromide as an additional therapy in severe intractable asthmatics
N. Suzuki, K. Ito, N. Yoshida, S. Hoshi, C. Ogawa, Y. Sano (Tokyo, Japan)
| |
Mycophenolate mofetil: an effective corticosteroid-sparing drug in steroid-dependent asthma
S. Minder, J. E. Salomon, C. Mordasini, L. P. Nicod (Bern, Switzerland)
| |
The inhalations of low-doses of cyclosporin A for bronchial asthma treatment
K. A. Zykov, S. N. Lebedev, A. V. Rvacheva, L. J. Matko, V. I. Shevelev, A. L. Pukhalsky, E. I. Kaznacheeva, E. I. Sokolov (Moscow, Russian Federation)
| |
Formoterol restores corticosteroid responses in corticosteroid-insensitive severe asthma
Y. To, M. Ito, I. M. Adcock, P. J. Barnes, K. Ito (London, United Kingdom)
| |
Formoterol delivered by multi-dose dry powder inhaler (MDDPI) improves nocturnal asthma symptoms
W. Busse, C. LaForce, D. Till, S. Stenglein (Madison, Raleigh, United States Of America; Horsham, United Kingdom)
| |
Adjustable dosing with budesonide/formoterol achieves sustained guideline ‘well-controlled asthma‘ following step down in treatment
R. Aalbers, A. Harris, I. Naya (Groningen, Netherlands; Lund, Sweden)
| |
Maintenance plus as-needed budesonide/formoterol is cost-effective compared with dose-titrated salmeterol/fluticasone
G. Johansson, P. E. Larsson, E. Andreasson (Uppsala, Lund, Sweden)
| |
Comparability of formoterol dry powder (DPI) and metered dose inhalers (MDI) in asthma
B. J. Lipworth, S. K. Das, A. H. Morice, B. J. O‘Connor (Dundee, St Albans, Hull, London, United Kingdom)
| |
No evidence for increase in serious asthma exacerbations with formoterol 24 μg twice daily
J. Wolfe, C. LaForce, B. Ziehmer, C. Orevillo, D. Till (San Jose, Raleigh, East Hanover, United States Of America)
| |
Comparable efficacy and tolerability of formoterol 12 μg or 24 μg twice daily in asthma patients
B. Friedman, W. Sokol, B. Ziehmer, C. Orevillo, D. Till (Fountain Valley, Newport Beach, East Hanover, United States Of America)
| |
Can control of severe asthma be achieved?
A. Bourdin, L. Halimi, P. Godard, P. Chanez (Montpellier, France)
| |